Journal: Scientific reports
This study analyzed the impact of tumor suppressor gene alterations (TSGAs) on outcomes in advanced non-small-cell lung cancer (aNSCLC) using a real-world clinical-genomic database of 201 patients profiled by next-generation sequencing.
Key findings include:
- STK11 and KEAP1 alterations were independently associated with poorer overall survival (OS).
- ALK alterations correlated with better OS.
- Co-mutations of KRAS with STK11 or KEAP1 further worsened survival.
Predictive insights for treatment response:
- CDKN2A/B alterations were linked to worse progression-free survival (PFS) on chemotherapy.
- TP53 alterations were associated with worse PFS on targeted therapy.
- CDKN2A/B, TP53, and KRAS alterations predicted improved PFS on immunotherapy.
These results highlight the prognostic and predictive value of extended genomic profiling beyond targetable mutations. They emphasize the complexity of lung cancer genetics and the need for personalized treatment strategies for patients with TSGAs.